"label","name","instanceType","description","uuid:ID","id","rationale"
"","Study Design 1","StudyDesign","The main design for the study","1698f806-c10e-406a-b552-a1ae4c950b92","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
